{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:45:52Z","timestamp":1793295952370,"version":"4.5.0"},"reference-count":189,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience & Biobehavioral Reviews"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.neubiorev.2023.105155","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T11:04:17Z","timestamp":1680519857000},"page":"105155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in the central nervous system"],"prefix":"10.1016","volume":"149","author":[{"given":"Andrew S.","family":"Bell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephin","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Rosoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk W.","family":"Lohoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.neubiorev.2023.105155_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001043","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke","volume":"2","author":"Abboud","year":"2007","journal-title":"Plos One"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.atherosclerosis.2012.04.006","article-title":"Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia","volume":"223","author":"Abifadel","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.neubiorev.2023.105155_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fnagi.2019.00120","article-title":"Proprotein convertase subtilisin\/kexin type 9, brain cholesterol homeostasis and potential implication for Alzheimer\u2019s disease","volume":"11","author":"Adorni","year":"2019","journal-title":"Front. Aging Neurosci."},{"issue":"12","key":"10.1016\/j.neubiorev.2023.105155_bib5","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/nn.4156","article-title":"The PsychENCODE project","volume":"18","author":"Akbarian","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neubiorev.2023.105155_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2020.104707","article-title":"Insulin signaling pathway and related molecules: role in neurodegeneration and Alzheimer's disease","volume":"135","author":"Akhtar","year":"2020","journal-title":"Neurochem. Int."},{"issue":"19","key":"10.1016\/j.neubiorev.2023.105155_bib7","doi-asserted-by":"crossref","first-page":"e1741","DOI":"10.1212\/WNL.0000000000006467","article-title":"Racial differences in recurrent ischemic stroke risk and recurrent stroke case fatality","volume":"91","author":"Albright","year":"2018","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.neubiorev.2023.105155_bib8","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/ijnp\/pyy060","article-title":"Risk of neuropsychiatric adverse effects of lipid-lowering drugs: a mendelian randomization study","volume":"21","author":"Alghamdi","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.neubiorev.2023.105155_bib9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1042\/CS20100094","article-title":"The vascular contribution to Alzheimer's disease","volume":"119","author":"Altman","year":"2010","journal-title":"Clin. Sci."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib10","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010838","article-title":"Pretreatment with PCSK9 inhibitor protects the brain against cardiac ischemia\/reperfusion injury through a reduction of neuronal inflammation and amyloid beta aggregation","volume":"8","author":"Apaijai","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105155_bib11","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.kint.2020.07.027","article-title":"Kidney-derived PCSK9\u2014a new driver of hyperlipidemia in nephrotic syndrome?","volume":"98","author":"Artunc","year":"2020","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib12","doi-asserted-by":"crossref","first-page":"18224","DOI":"10.1038\/srep18224","article-title":"The Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-Analysis","volume":"5","author":"Au","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrd1284","article-title":"Therapeutic vaccination for chronic diseases: a new class of drugs in sight","volume":"3","author":"Bachmann","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","article-title":"The blood\u2013brain barrier: an overview: structure, regulation, and clinical implications","volume":"16","author":"Ballabh","year":"2004","journal-title":"Neurobiol. Dis."},{"issue":"34","key":"10.1016\/j.neubiorev.2023.105155_bib15","article-title":"Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemia: A case report","volume":"99","author":"Bayona","year":"2020","journal-title":"Med. (Baltim. )"},{"issue":"24","key":"10.1016\/j.neubiorev.2023.105155_bib16","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1016\/j.cub.2006.10.029","article-title":"ApoE receptor 2 controls neuronal survival in the adult brain","volume":"16","author":"Beffert","year":"2006","journal-title":"Curr. Biol."},{"issue":"21","key":"10.1016\/j.neubiorev.2023.105155_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026122","article-title":"Comparing the relationships of genetically proxied PCSK9 inhibition with mood disorders, cognition, and dementia between men and women: a drug-target mendelian randomization study","volume":"11","author":"Bell","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"47","key":"10.1016\/j.neubiorev.2023.105155_bib18","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol *","volume":"279","author":"Benjannet","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neubiorev.2023.105155_bib19","doi-asserted-by":"crossref","first-page":"j1648","DOI":"10.1136\/bmj.j1648","article-title":"Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer\u2019s disease and Parkinson\u2019s disease: Mendelian randomisation study","volume":"357","author":"Benn","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105155_bib20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.11.002","article-title":"Statins, RISK OF DEMENTIA, AND COGNITIVE FUNCTION: SECONDARY ANALYSIS OF THE GINKGO EVALUATION OF MEMORY STudy","volume":"21","author":"Bettermann","year":"2012","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"11","key":"10.1016\/j.neubiorev.2023.105155_bib21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1136\/jech.2009.100826","article-title":"Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment","volume":"65","author":"Beydoun","year":"2011","journal-title":"J. Epidemiol. Community Health"},{"issue":"11","key":"10.1016\/j.neubiorev.2023.105155_bib22","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/cyto.a.20346","article-title":"Proapoptotic effects of NARC 1 (= PCSK9), the gene encoding a novel serine proteinase","volume":"69A","author":"Bingham","year":"2006","journal-title":"Cytom. Part A"},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib23","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1161\/01.ATV.0000120374.59826.1b","article-title":"Brain Cholesterol: Long Secret Life Behind a Barrier","volume":"24","author":"Bj\u00f6rkhem","year":"2004","journal-title":"Arterioscler., Thromb., Vasc. Biol."},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105155_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.mam.2009.02.001","article-title":"Oxysterols and neurodegenerative diseases","volume":"30","author":"Bj\u00f6rkhem","year":"2009","journal-title":"Mol. Asp. Med."},{"issue":"12","key":"10.1016\/j.neubiorev.2023.105155_bib25","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.jacc.2020.01.033","article-title":"High-density lipoproteins are the main carriers of PCSK9 in the circulation","volume":"75","author":"Burnap","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064145","article-title":"Proprotein convertase subtilisin\/Kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)","volume":"8","author":"Canuel","year":"2013","journal-title":"PLOS ONE"},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105155_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MOL.0000000000000180","article-title":"Role of PCSK9 beyond liver involvement","volume":"26","author":"Cariou","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.neubiorev.2023.105155_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2017.06.336","article-title":"PCSK9 cerebrospinal fluid concentrations are not increased in Alzheimer\u2019s disease","volume":"263","author":"Cariou","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.neubiorev.2023.105155_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2016.09.023","article-title":"PCSK9 inhibitors: a new era in stroke prevention?","volume":"37","author":"Castilla-Guerra","year":"2017","journal-title":"Eur. J. Intern. Med."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: a new era of lipid lowering therapy","volume":"9","author":"Chaudhary","year":"2017","journal-title":"World J. Cardiol."},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib31","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11745-014-3895-6","article-title":"PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day","volume":"49","author":"Chen","year":"2014","journal-title":"Lipids"},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105155_bib32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib33","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1073\/pnas.051630598","article-title":"An orchestrated gene expression component of neuronal programmed cell death revealed by cDNA array analysis","volume":"98","author":"Chiang","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neubiorev.2023.105155_bib34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3389\/fneur.2019.00441","article-title":"Variability in total cholesterol concentration is associated with the risk of dementia: a nationwide population-based Cohort study","volume":"10","author":"Chung","year":"2019","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.neubiorev.2023.105155_bib35","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, Low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105155_bib36","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The genotype-tissue expression (GTEx) project","volume":"45","author":"Consortium","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neubiorev.2023.105155_bib37","first-page":"10","article-title":"Lipid-binding proteins in brain health and disease","author":"Corraliza-Gomez","year":"2019","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105155_bib38","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3233\/JAD-170993","article-title":"PCSK9 concentrations in cerebrospinal fluid are not specifically increased in Alzheimer's disease","volume":"62","author":"Courtemanche","year":"2018","journal-title":"J. Alzheimers Dis."},{"issue":"43","key":"10.1016\/j.neubiorev.2023.105155_bib39","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","article-title":"A cholesterol-lowering VLP vaccine that targets PCSK9","volume":"33","author":"Crossey","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-017-0297-z","article-title":"Alzheimer's disease prevention: from risk factors to early intervention","volume":"9","author":"Crous-Bou","year":"2017","journal-title":"Alzheimers Res Ther."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105155_bib41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/eurheartj\/ehy357","article-title":"PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor","volume":"40","author":"Da Dalt","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.neubiorev.2023.105155_bib42","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.atherosclerosis.2016.03.024","article-title":"Cholesterol-lowering interventions and stroke: Insights from IMPROVE-IT","volume":"248","author":"De Caterina","year":"2016","journal-title":"Atherosclerosis"},{"issue":"19","key":"10.1016\/j.neubiorev.2023.105155_bib43","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","article-title":"Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins","volume":"60","author":"Dias","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.neubiorev.2023.105155_bib44","first-page":"1341","volume":"391","author":"Dieckmann","year":"2010","journal-title":"Lipoprotein Recept. \u2013 Evol. Anc. Multifunct. Recept. Fam."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105155_bib45","first-page":"287","article-title":"Central nervous system: cholesterol turnover, brain development and neurodegeneration","volume":"390","author":"Dietschy","year":"2009"},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib46","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105155_bib47","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/cvr\/cvy079","article-title":"PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages","volume":"114","author":"Ding","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.neubiorev.2023.105155_bib48","doi-asserted-by":"crossref","first-page":"9340480","DOI":"10.1155\/2020\/9340480","article-title":"Association of the rs562556 PCSK9 Gene Polymorphism with Reduced Mortality in Severe Malaria among Malian Children","volume":"2020","author":"Fedoryak","year":"2020","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"issue":"9","key":"10.1016\/j.neubiorev.2023.105155_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.11130","article-title":"A genetic approach to the association between PCSK9 and sepsis","volume":"2","author":"Feng","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib50","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2011.11.026","article-title":"Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels","volume":"220","author":"Ferri","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.neubiorev.2023.105155_bib51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trsl.2015.10.004","article-title":"Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence","volume":"173","author":"Ferri","year":"2016","journal-title":"Transl. Res."},{"key":"10.1016\/j.neubiorev.2023.105155_bib52","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2016.07.910","article-title":"PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. A","volume":"253","author":"Ferri","year":"2016","journal-title":"therosclerosis"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neubiorev.2023.105155_bib54","first-page":"62","article-title":"PCSK9 is not secreted from mature differentiated intestinal\u00a0cells","author":"Fran\u00e7ois","year":"2021","journal-title":"J. Lipid Res."},{"issue":"9","key":"10.1016\/j.neubiorev.2023.105155_bib55","first-page":"883","article-title":"APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo","volume":"1862","author":"Fu","year":"2017","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Mol. Cell Biol. Lipids"},{"issue":"12","key":"10.1016\/j.neubiorev.2023.105155_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114469","article-title":"Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management","volume":"9","author":"Galabova","year":"2014","journal-title":"PLOS ONE"},{"issue":"9","key":"10.1016\/j.neubiorev.2023.105155_bib57","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1161\/ATVBAHA.120.314194","article-title":"Circulating rather than intestinal pcsk9 (proprotein convertase subtilisin kexin type 9) regulates postprandial lipemia in mice","volume":"40","author":"Gar\u00e7on","year":"2020","journal-title":"Arterioscler., Thromb., Vasc. Biol."},{"issue":"9","key":"10.1016\/j.neubiorev.2023.105155_bib58","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/sj.cdd.4401950","article-title":"Mechanisms of cytochrome c release from mitochondria","volume":"13","author":"Garrido","year":"2006","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105155_bib59","first-page":"150","article-title":"Statins and their effect on cognition:Let\u2019s clear up the confusion","volume":"148","author":"Gauthier","year":"2015","journal-title":"Can. Pharm. J. \/ Rev. Des. Pharm. du Can."},{"key":"10.1016\/j.neubiorev.2023.105155_bib60","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ebiom.2018.11.032","article-title":"Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors","volume":"38","author":"Genga","year":"2018","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib61","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/clc.22678","volume":"40","author":"Giugliano","year":"2017","journal-title":"Clin. Cardiol."},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105155_bib62","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1194\/jlr.M800027-JLR200","article-title":"Plasma PCSK9 preferentially reduces liver LDL receptors in mice *","volume":"49","author":"Grefhorst","year":"2008","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib63","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/liv.14711","article-title":"PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD","volume":"41","author":"Grimaudo","year":"2021","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.115.020912","article-title":"The role of proprotein convertase subtilisin\/Kexin type 9 in nephrotic syndrome-associated hypercholesterolemia","volume":"134","author":"Haas","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105155_bib65","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1542-3565(04)00622-6","article-title":"High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics","volume":"3","author":"Habib","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.neubiorev.2023.105155_bib66","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.12659\/MSM.892091","article-title":"Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations","volume":"20","author":"Han","year":"2014","journal-title":"Med Sci. Monit."},{"issue":"33","key":"10.1016\/j.neubiorev.2023.105155_bib67","doi-asserted-by":"crossref","first-page":"8354","DOI":"10.1523\/JNEUROSCI.0616-08.2008","article-title":"Microglial dysfunction and defective \u03b2-amyloid clearance pathways in aging Alzheimer's disease mice","volume":"28","author":"Hickman","year":"2008","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib68","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1471-4159.2004.03007.x","article-title":"Multiple pathways of apolipoproteinE signaling in primary neurons","volume":"93","author":"Hoe","year":"2005","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105155_bib69","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41569-020-00493-1","article-title":"Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development","volume":"18","author":"Holmes","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib70","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/eurheartj\/ehx373","article-title":"Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke","volume":"39","author":"Hopewell","year":"2017","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.neubiorev.2023.105155_bib71","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/embor.2008.132","article-title":"PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1","volume":"9","author":"Jonas","year":"2008","journal-title":"EMBO Rep."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105155_bib72","article-title":"PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke","volume":"10","author":"Kent","year":"2017","journal-title":"Circ.: Cardiovasc. Genet."},{"key":"10.1016\/j.neubiorev.2023.105155_bib73","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2020.08.018","article-title":"Meta-analysis of inclisiran for the treatment of hypercholesterolemia","volume":"134","author":"Khan","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.neubiorev.2023.105155_bib74","article-title":"PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis","volume":"377","author":"Khan","year":"2022","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib75","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1161\/STROKEAHA.108.539643","article-title":"Low level of low-density lipoprotein cholesterol increases hemorrhagic transformation in large artery atherothrombosis but not in cardioembolism","volume":"40","author":"Kim","year":"2009","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.neubiorev.2023.105155_bib76","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1074\/jbc.M112.421370","article-title":"Low density lipoprotein binds to proprotein convertase subtilisin\/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation *","volume":"288","author":"Kosenko","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib77","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2008.02.003","article-title":"Effect of protein convertase subtilisin\/kexin type 9 (PCSK9) 46L gene polymorphism on LDL cholesterol concentration in a Polish adult population","volume":"94","author":"Kostrzewa","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"11","key":"10.1016\/j.neubiorev.2023.105155_bib78","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00018-012-0977-6","article-title":"PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling","volume":"69","author":"Kysenius","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"issue":"11","key":"10.1016\/j.neubiorev.2023.105155_bib79","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105155_bib80","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.neuron.2014.08.005","article-title":"More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration","volume":"83","author":"Lane-Donovan","year":"2014","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105155_bib81","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jhepr.2019.10.009","article-title":"Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice","volume":"1","author":"Lebeau","year":"2019","journal-title":"JHEP Rep."},{"key":"10.1016\/j.neubiorev.2023.105155_bib83","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1172\/JCI128650","article-title":"The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury","volume":"131","author":"Lebeau","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105155_bib84","first-page":"1163","article-title":"PCSK9 is increased in cerebrospinal fluid of individuals with alcohol use disorder","volume":"43","author":"Lee","year":"2019"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib85","doi-asserted-by":"crossref","first-page":"17167","DOI":"10.1038\/s41598-019-53603-6","article-title":"PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease","volume":"9","author":"Lee","year":"2019","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105155_bib86","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/jcm10081758","article-title":"PCSK9 and the gut-liver-brain axis: a novel therapeutic target for immune regulation in alcohol use disorder","volume":"10","author":"Lee","year":"2021","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105155_bib87","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib88","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3892\/mmr.2017.6803","article-title":"Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis","volume":"16","author":"Li","year":"2017","journal-title":"Mol. Med Rep."},{"issue":"9","key":"10.1016\/j.neubiorev.2023.105155_bib89","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1194\/jlr.M006635","article-title":"PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain","volume":"51","author":"Liu","year":"2010","journal-title":"J. Lipid Res"},{"issue":"50","key":"10.1016\/j.neubiorev.2023.105155_bib90","doi-asserted-by":"crossref","first-page":"17068","DOI":"10.1523\/JNEUROSCI.4067-10.2010","article-title":"Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration","volume":"30","author":"Liu","year":"2010","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105155_bib91","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0195-668X(02)00750-9","article-title":"Acute infections in children are accompanied by oxidative modification of LDL and decrease of HDL cholesterol, and are followed by thickening of carotid intima\u2013media","volume":"24","author":"Liuba","year":"2003","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.neubiorev.2023.105155_bib92","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/mp.2017.168","article-title":"Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder","volume":"23","author":"Lohoff","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2023.105155_bib93","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13006","article-title":"Epigenetics of alcohol use disorder\u2014A review of recent advances in DNA methylation profiling","author":"Longley","year":"2021","journal-title":"Addict. Biol."},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105155_bib94","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1194\/jlr.M800542-JLR200","article-title":"Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice","volume":"50","author":"Luo","year":"2009","journal-title":"J. Lipid Res"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib95","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5114\/aoms\/127226","article-title":"PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study","volume":"17","author":"Lyall","year":"2021","journal-title":"Arch. Med Sci."},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105155_bib96","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0304-3940(02)00942-4","article-title":"Low-density lipoprotein receptor-related protein 8 (apolipoprotein E receptor 2) gene polymorphisms in Alzheimer's disease","volume":"332","author":"Ma","year":"2002","journal-title":"Neurosci. Lett."},{"issue":"9","key":"10.1016\/j.neubiorev.2023.105155_bib97","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1177\/2047487319831500","article-title":"Changes in circulating pro-protein convertase subtilisin\/kexin type 9 levels \u2013 experimental and clinical approaches with lipid-lowering agents","volume":"26","author":"Macchi","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105155_bib98","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ajpath.2021.04.016","article-title":"Proprotein convertase subtilisin\/Kexin Type 9: a view beyond the canonical cholesterol-lowering impact","volume":"191","author":"Macchi","year":"2021","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib99","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacl.2018.05.012","article-title":"PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?","volume":"12","author":"Mannarino","year":"2018","journal-title":"J. Clin. Lipidol."},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib100","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/ijms21051550","article-title":"In silico insights into protein\u2013protein interaction disruptive mutations in the PCSK9-LDLR complex","volume":"21","author":"Martin","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.neubiorev.2023.105155_bib101","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1194\/jlr.M300203-JLR200","article-title":"Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice","volume":"44","author":"Maxwell","year":"2003","journal-title":"J. Lipid Res"},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib102","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/ATVBAHA.108.181586","article-title":"Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia","volume":"29","author":"May","year":"2009","journal-title":"Arterioscler., Thromb., Vasc. Biol."},{"issue":"7","key":"10.1016\/j.neubiorev.2023.105155_bib103","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1161\/ATVBAHA.112.300263","article-title":"Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1","volume":"33","author":"May","year":"2013","journal-title":"Arterioscler., Thromb., Vasc. Biol."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105155_bib104","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00018-022-04237-x","article-title":"PCSK9 acts as a key regulator of A\u03b2 clearance across the blood\u2013brain barrier","volume":"79","author":"Mazura","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib105","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.mehy.2007.03.018","article-title":"Of PCSK9, cholesterol homeostasis and parasitic infections: possible survival benefits of loss-of-function PCSK9 genetic polymorphisms","volume":"69","author":"Mbikay","year":"2007","journal-title":"Med. Hypotheses"},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105155_bib106","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.febslet.2009.12.018","article-title":"PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities","volume":"584","author":"Mbikay","year":"2010","journal-title":"FEBS Lett."},{"issue":"12","key":"10.1016\/j.neubiorev.2023.105155_bib107","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCULATIONAHA.117.029785","article-title":"PCSK9 variants, low-density lipoprotein cholesterol, and neurocognitive impairment","volume":"137","author":"Mefford","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210808","article-title":"PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort","volume":"14","author":"Mitchell","year":"2019","journal-title":"PLOS ONE"},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105155_bib109","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.drudis.2017.01.006","article-title":"PCSK9 and diabetes: is there a link?","volume":"22","author":"Momtazi","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12916-019-1457-8","article-title":"Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis","volume":"17","author":"Momtazi-Borojeni","year":"2019","journal-title":"BMC Med."},{"issue":"7859","key":"10.1016\/j.neubiorev.2023.105155_bib111","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib112","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1536\/ihj.13-383","article-title":"Therapeutic vaccines for hypertension and dyslipidemia","volume":"55","author":"Nakagami","year":"2014","journal-title":"Int. Heart J."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib113","article-title":"Genetic assessment of potential long-term on-target side effects of PCSK9 (Proprotein convertase subtilisin\/kexin type 9) inhibitors","volume":"12","author":"Nelson","year":"2019","journal-title":"Circ.: Genom. Precis. Med."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib114","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1471-4159.2009.05917.x","article-title":"Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats","volume":"109","author":"Nieweg","year":"2009","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105155_bib115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/13543784.2018.1442435","article-title":"Inclisiran for the treatment of dyslipidemia","volume":"27","author":"Nishikido","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib116","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.atherosclerosis.2009.06.023","article-title":"Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles","volume":"208","author":"Norata","year":"2010","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105155_bib117","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11606-014-3115-3","article-title":"Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Ott","year":"2015","journal-title":"J. Gen. Intern. Med."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib118","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/0891988718764330","article-title":"Loss-of-function PCSK9 mutations are not associated with Alzheimer disease","volume":"31","author":"Paquette","year":"2018","journal-title":"J. Geriatr. Psychiatry Neurol."},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105155_bib119","doi-asserted-by":"crossref","DOI":"10.1592\/phco.30.6.625","article-title":"Changes in memory function and neuronal activation associated with atorvastatin therapy","volume":"30","author":"Parker","year":"2010","journal-title":"Pharmacother.: J. Hum. Pharmacol. Drug Ther."},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105155_bib120","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s11255-017-1505-2","article-title":"PCSK9 in chronic kidney disease","volume":"49","author":"Pavlakou","year":"2017","journal-title":"Int. Urol. Nephrol."},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105155_bib121","article-title":"Substantial PCSK9 inactivation in \u03b2-cells does not modify glucose homeostasis or insulin secretion in mice","volume":"1866","author":"Peyot","year":"2021","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Mol. Cell Biol. Lipids"},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105155_bib122","first-page":"2787","article-title":"PCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways","volume":"8","author":"Piao","year":"2015","journal-title":"Int J. Clin. Exp. Pathol."},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105155_bib123","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220254","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in Alzheimer\u2019s disease: A genetic and proteomic multi-cohort study","volume":"14","author":"Picard","year":"2019","journal-title":"PLOS ONE"},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib124","first-page":"472","article-title":"Lipid and lipoprotein measurements and the risk of ischemic vascular events. Framingham Study","volume":"84","author":"Pikula","year":"2015"},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib125","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.str.2007.04.004","article-title":"The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol","volume":"15","author":"Piper","year":"2007","journal-title":"Structure"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116701","article-title":"Lrp4 domains differentially regulate limb\/brain development and synaptic plasticity","volume":"10","author":"Pohlkamp","year":"2015","journal-title":"PLOS ONE"},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105155_bib127","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1471-4159.2006.03928.x","article-title":"Implication of the proprotein convertase NARC-1\/PCSK9 in the development of the nervous system","volume":"98","author":"Poirier","year":"2006","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105155_bib128","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2*","volume":"283","author":"Poirier","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib129","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1194\/jlr.M033969","article-title":"PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population [S]","volume":"54","author":"Postmus","year":"2013","journal-title":"J. Lipid Res"},{"issue":"20","key":"10.1016\/j.neubiorev.2023.105155_bib130","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.neubiorev.2023.105155_bib131","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7546","key":"10.1016\/j.neubiorev.2023.105155_bib132","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib133","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jcp.21519","article-title":"Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9","volume":"217","author":"Ranheim","year":"2008","journal-title":"J. Cell. Physiol."},{"issue":"7","key":"10.1016\/j.neubiorev.2023.105155_bib134","article-title":"Large-scale phenome-wide association study of PCSK9 variants demonstrates protection against ischemic stroke","volume":"11","author":"Rao","year":"2018","journal-title":"Circ.: Genom. Precis. Med."},{"issue":"15","key":"10.1016\/j.neubiorev.2023.105155_bib135","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL Cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib136","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamaneurol.2013.5390","article-title":"Associations Between Serum Cholesterol Levels and Cerebral Amyloidosis","volume":"71","author":"Reed","year":"2014","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/j.neubiorev.2023.105155_bib137","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/hmg\/ddq079","article-title":"Analysis of lipid pathway genes indicates association of sequence variation near SREBF1\/TOM1L2\/ATPAF2 with dementia risk","volume":"19","author":"Reynolds","year":"2010","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105155_bib138","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ajhg.2021.01.012","article-title":"Genetic control of the human brain proteome","volume":"108","author":"Robins","year":"2021","journal-title":"Am. J. Hum. Genet"},{"issue":"16","key":"10.1016\/j.neubiorev.2023.105155_bib139","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib140","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105155_bib141","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.5844","article-title":"Association of high-intensity binge drinking with lipid and liver function enzyme levels","volume":"2","author":"Rosoff","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.neubiorev.2023.105155_bib142","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.alcohol.2020.02.164","article-title":"Lipid profile dysregulation predicts alcohol withdrawal symptom severity in individuals with alcohol use disorder","volume":"86","author":"Rosoff","year":"2020","journal-title":"Alcohol"},{"issue":"7","key":"10.1016\/j.neubiorev.2023.105155_bib143","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jacc.2022.05.041","article-title":"Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function","volume":"80","author":"Rosoff","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105155_bib144","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.neubiorev.2023.105155_bib145","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1194\/jlr.M014118","article-title":"PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke [S]","volume":"52","author":"Rousselet","year":"2011","journal-title":"J. Lipid Res"},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib146","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","article-title":"Liver fat accumulation is associated with circulating PCSK9","volume":"48","author":"Ruscica","year":"2016","journal-title":"Ann. Med."},{"issue":"9","key":"10.1016\/j.neubiorev.2023.105155_bib147","first-page":"991","article-title":"Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders","volume":"1863","author":"Ruscica","year":"2018","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Mol. Cell Biol. Lipids"},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105155_bib148","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jacl.2015.08.005","article-title":"Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes\/diabetes risk","volume":"9","author":"Saavedra","year":"2015","journal-title":"J. Clin. Lipidol."},{"issue":"18","key":"10.1016\/j.neubiorev.2023.105155_bib149","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105155_bib150","first-page":"659","article-title":"Race-ethnic differences in stroke risk factors among hospitalized patients with cerebral infarction. The Northern Manhattan Stroke Study","volume":"45","author":"Sacco","year":"1995"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib151","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41525-019-0078-7","article-title":"A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR","volume":"4","author":"Safarova","year":"2019","journal-title":"npj Genom. Med."},{"issue":"9716","key":"10.1016\/j.neubiorev.2023.105155_bib152","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib153","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib154","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16969-0","article-title":"Genetic drug target validation using Mendelian randomisation","volume":"11","author":"Schmidt","year":"2020","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105155_bib155","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.bbrc.2008.04.004","article-title":"Secreted proprotein convertase subtilisin\/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo","volume":"370","author":"Schmidt","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib156","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105155_bib157","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.neubiorev.2023.105155_bib158","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib159","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11886-017-0848-8","article-title":"Genetic architecture of familial hypercholesterolaemia","volume":"19","author":"Sharifi","year":"2017","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.neubiorev.2023.105155_bib160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00041444-200512000-00004","article-title":"No genetic association between PCSK9 polymorphisms and Alzheimer's disease and plasma cholesterol level in Japanese patients","volume":"15","author":"Shibata","year":"2005","journal-title":"Psychiatr. Genet."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib161","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1023\/A:1009625323388","article-title":"Apoptosis in Alzheimer's disease\u2014an update","volume":"5","author":"Shimohama","year":"2000","journal-title":"Apoptosis"},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib162","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12031-014-0238-2","article-title":"Effect of E670G polymorphism in PCSK9 gene on the risk and severity of coronary heart disease and ischemic stroke in a tunisian Cohort","volume":"53","author":"Slimani","year":"2014","journal-title":"J. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib163","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/exnr.1995.1025","article-title":"Evidence for apoptotic cell death in Alzheimer's disease","volume":"133","author":"Smale","year":"1995","journal-title":"Exp. Neurol."},{"issue":"11","key":"10.1016\/j.neubiorev.2023.105155_bib164","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239752","article-title":"PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort","volume":"15","author":"Small","year":"2020","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib165","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1172\/JCI81108","article-title":"Endothelial LRP1 transports amyloid-\u03b21\u201342 across the blood-brain barrier","volume":"126","author":"Storck","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"12","key":"10.1016\/j.neubiorev.2023.105155_bib166","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/embor.2011.205","article-title":"Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH","volume":"12","author":"Surdo","year":"2011","journal-title":"EMBO Rep."},{"issue":"6","key":"10.1016\/j.neubiorev.2023.105155_bib168","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40264-015-0296-6","article-title":"PCSK9 inhibitors and neurocognitive adverse events: exploring the fda directive and a proposal for N-of-1 trials","volume":"38","author":"Swiger","year":"2015","journal-title":"Drug Saf."},{"issue":"24","key":"10.1016\/j.neubiorev.2023.105155_bib169","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.113.001592","article-title":"Serum proprotein convertase subtilisin\/kexin type 9 and cell surface low-density lipoprotein receptor","volume":"127","author":"Tavori","year":"2013","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.neubiorev.2023.105155_bib170","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1161\/CIRCULATIONAHA.116.025233","article-title":"Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies","volume":"135","author":"Toth","year":"2017","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.neubiorev.2023.105155_bib171","doi-asserted-by":"crossref","first-page":"e1176","DOI":"10.1212\/WNL.0000000000007091","article-title":"Relative effects of LDL-C on ischemic stroke and coronary disease: A Mendelian randomization study","volume":"92","author":"Valdes-Marquez","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105155_bib172","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1053\/j.gastro.2007.06.019","article-title":"Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice","volume":"133","author":"van der Velde","year":"2007","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105155_bib173","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41587-021-00975-8","article-title":"CRISPR base editing lowers cholesterol in monkeys","volume":"39","author":"van Kampen","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.neubiorev.2023.105155_bib174","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jacc.2018.06.043","article-title":"Effect of long-term low lipoproteins on neurocognitive function","volume":"72","author":"Verbeek","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.neubiorev.2023.105155_bib175","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0741-8329(97)00133-X","article-title":"Ethanol enhances cholesterol synthesis and secretion in human hepatomal cells","volume":"15","author":"Visioli","year":"1998","journal-title":"Alcohol"},{"issue":"3","key":"10.1016\/j.neubiorev.2023.105155_bib176","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/cvr\/cvu148","article-title":"HDL and cholesterol handling in the brain","volume":"103","author":"Vitali","year":"2014","journal-title":"Cardiovasc. Res."},{"issue":"23","key":"10.1016\/j.neubiorev.2023.105155_bib177","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1021\/acschemneuro.2c00663","article-title":"PCSK9 base editing therapeutics and ischemic stroke","volume":"13","author":"Wagner","year":"2022","journal-title":"ACS Chem. Neurosci."},{"issue":"8","key":"10.1016\/j.neubiorev.2023.105155_bib178","first-page":"5076","article-title":"Novel apoE receptor mimetics reduce LPS-induced microglial inflammation","volume":"11","author":"Wang","year":"2019","journal-title":"Am. J. Transl. Res"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib179","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1476-511X-13-175","article-title":"LDL receptor knock-out mice show impaired spatial cognition with hippocampal vulnerability to apoptosis and deficits in synapses","volume":"13","author":"Wang","year":"2014","journal-title":"Lipids Health Dis."},{"issue":"7","key":"10.1016\/j.neubiorev.2023.105155_bib180","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1161\/STROKEAHA.113.001326","article-title":"Cholesterol Levels and Risk of Hemorrhagic","volume":"44","author":"Wang","year":"2013","journal-title":"Stroke Stroke"},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib181","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/ATVBAHA.116.307227","article-title":"CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo\u2014Brief Report","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler., Thromb., Vasc. Biol."},{"key":"10.1016\/j.neubiorev.2023.105155_bib182","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.14506.1","article-title":"Current understanding of Alzheimer's disease diagnosis and treatment","volume":"7","author":"Weller","year":"2018","journal-title":"F1000Res."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib183","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25642","article-title":"Lipid lowering and Alzheimer disease risk: A mendelian randomization study","volume":"87","author":"Williams","year":"2020","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.neubiorev.2023.105155_bib184","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/jamaneurol.2019.0648","article-title":"Association of early-onset alzheimer disease with elevated low-density lipoprotein cholesterol levels and rare genetic coding variants of APOB","volume":"76","author":"Wingo","year":"2019","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.neubiorev.2023.105155_bib185","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.3892\/etm.2017.4218","article-title":"PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways","volume":"13","author":"Xu","year":"2017","journal-title":"Exp. Ther. Med"},{"issue":"32","key":"10.1016\/j.neubiorev.2023.105155_bib186","doi-asserted-by":"crossref","first-page":"29342","DOI":"10.1074\/jbc.M202411200","article-title":"Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP)*","volume":"277","author":"You","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.neubiorev.2023.105155_bib187","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib188","doi-asserted-by":"crossref","first-page":"6","DOI":"10.35946\/arcr.v35.1.02","article-title":"Alcohol metabolism and epigenetics changes","volume":"35","author":"Zakhari","year":"2013","journal-title":"Alcohol Res."},{"issue":"10","key":"10.1016\/j.neubiorev.2023.105155_bib189","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00228-021-03149-2","article-title":"A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9","volume":"77","author":"Zeitlinger","year":"2021","journal-title":"Eur. J. Clin. Pharm."},{"issue":"7","key":"10.1016\/j.neubiorev.2023.105155_bib190","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3349\/ymj.2019.60.7.659","article-title":"Associations for BCO2, PCSK9, and TR1B1 polymorphism and lifestyle factors with ischemic stroke: a nested case-control study","volume":"60","author":"Zhao","year":"2019","journal-title":"Yonsei Med. J."},{"issue":"1","key":"10.1016\/j.neubiorev.2023.105155_bib191","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3233\/JAD-160411","article-title":"Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer's disease","volume":"55","author":"Zimetti","year":"2017","journal-title":"J. Alzheimers Dis."}],"container-title":["Neuroscience & Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763423001240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763423001240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:30:20Z","timestamp":1758969020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763423001240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":189,"alternative-id":["S0149763423001240"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105155","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in the central nervous system","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105155"}}